WallStreetZenWallStreetZen

NASDAQ: BIIB
Biogen Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BIIB

Based on 9 analysts offering 12 month price targets for Biogen Inc

Min Forecast
$121.00-33.26%
Avg Forecast
$168.33-7.15%
Max Forecast
$210.00+15.83%

Should I buy or sell BIIB stock?

Based on 9 analysts offering ratings for Biogen Inc.

Buy
Strong Buy
2 analysts 22.22%
Buy
2 analysts 22.22%
Hold
5 analysts 55.56%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BIIB's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates BIIB as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their BIIB stock forecasts and price targets.

BIIB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-21
lockedlocked$00.00+00.00%2025-11-06
lockedlocked$00.00+00.00%2025-11-03
lockedlocked$00.00+00.00%2025-10-31
lockedlocked$00.00+00.00%2025-10-10Find Out Why
Jefferies
Top 35%
66
Strong BuyInitiates Coverage On$190.00+4.80%2025-09-25Find out why
Citigroup
Top 12%
89
HoldMaintains$135.00-25.54%2025-08-01
HC Wainwright & Co.
Top 1%
100
BuyMaintains$194.00+7.00%2025-08-01
Wedbush
Top 5%
96
HoldReiterates$121.00-33.26%2025-06-12

1 of 1

Forecast return on equity

Is BIIB forecast to generate an efficient return?

Company
13.49%
Industry
-57.8%
Market
228.52%
BIIB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BIIB forecast to generate an efficient return on assets?

Company
8.41%
Industry
22.86%
BIIB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BIIB earnings per share forecast

What is BIIB's earnings per share in the next 3 years based on estimates from 39 analysts?

Avg 1 year Forecast
$15.19+38.19%
Avg 2 year Forecast
$15.36+39.76%
Avg 3 year Forecast
$16.11+46.59%
BIIB's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

BIIB revenue forecast

What is BIIB's revenue in the next 3 years based on estimates from 38 analysts?

Avg 1 year Forecast
$10.0B-0.41%
Avg 2 year Forecast
$9.5B-5.71%
Avg 3 year Forecast
$9.4B-6.14%
BIIB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BIIB earnings growth forecast

How is BIIB forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
13.32%
Industry
33.31%
Market
42.88%
BIIB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
BIIB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
BIIB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

BIIB revenue growth forecast

How is BIIB forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
-2.42%
Industry
6.3%
Market
25.67%
BIIB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BIIB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BIIB vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
BIIB$181.30$168.33-7.15%Buy
GRFS$8.85$10.30+16.38%Hold
OGN$7.14$10.50+47.06%Sell
AMRN$16.54$12.00-27.45%Strong Sell
SCLX$19.15N/AN/A
View Top General Drug Manufacturer Stocks

Biogen Stock Forecast FAQ

Is Biogen Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NASDAQ: BIIB) stock is to Buy BIIB stock.

Out of 9 analysts, 2 (22.22%) are recommending BIIB as a Strong Buy, 2 (22.22%) are recommending BIIB as a Buy, 5 (55.56%) are recommending BIIB as a Hold, 0 (0%) are recommending BIIB as a Sell, and 0 (0%) are recommending BIIB as a Strong Sell.

If you're new to stock investing, here's how to buy Biogen stock.

What is BIIB's earnings growth forecast for 2025-2027?

(NASDAQ: BIIB) Biogen's forecast annual earnings growth rate of 13.32% is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 33.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.

Biogen's earnings in 2025 is $1,608,500,000.On average, 39 Wall Street analysts forecast BIIB's earnings for 2025 to be $2,227,908,724, with the lowest BIIB earnings forecast at $2,100,453,790, and the highest BIIB earnings forecast at $2,333,666,392. On average, 39 Wall Street analysts forecast BIIB's earnings for 2026 to be $2,253,244,206, with the lowest BIIB earnings forecast at $1,582,888,174, and the highest BIIB earnings forecast at $2,638,044,266.

In 2027, BIIB is forecast to generate $2,363,402,942 in earnings, with the lowest earnings forecast at $1,884,801,450 and the highest earnings forecast at $2,814,263,035.

What is BIIB's revenue growth forecast for 2025-2027?

(NASDAQ: BIIB) Biogen's forecast annual revenue growth rate of -2.42% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.

Biogen's revenue in 2025 is $10,065,900,000.On average, 38 Wall Street analysts forecast BIIB's revenue for 2025 to be $1,470,690,276,800, with the lowest BIIB revenue forecast at $1,394,845,202,176, and the highest BIIB revenue forecast at $1,560,472,067,264. On average, 38 Wall Street analysts forecast BIIB's revenue for 2026 to be $1,392,351,263,552, with the lowest BIIB revenue forecast at $1,232,885,893,888, and the highest BIIB revenue forecast at $1,513,380,637,952.

In 2027, BIIB is forecast to generate $1,386,043,065,856 in revenue, with the lowest revenue forecast at $1,265,160,393,728 and the highest revenue forecast at $1,559,885,258,176.

What is BIIB's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: BIIB) forecast ROA is 8.41%, which is lower than the forecast US Drug Manufacturers - General industry average of 22.86%.

What is BIIB's Price Target?

According to 9 Wall Street analysts that have issued a 1 year BIIB price target, the average BIIB price target is $168.33, with the highest BIIB stock price forecast at $210.00 and the lowest BIIB stock price forecast at $121.00.

On average, Wall Street analysts predict that Biogen's share price could fall to $168.33 by Nov 21, 2026. The average Biogen stock price prediction forecasts a potential downside of 7.15% from the current BIIB share price of $181.30.

What is BIIB's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BIIB) Biogen's current Earnings Per Share (EPS) is $10.99. On average, analysts forecast that BIIB's EPS will be $15.19 for 2025, with the lowest EPS forecast at $14.32, and the highest EPS forecast at $15.91. On average, analysts forecast that BIIB's EPS will be $15.36 for 2026, with the lowest EPS forecast at $10.79, and the highest EPS forecast at $17.98. In 2027, BIIB's EPS is forecast to hit $16.11 (min: $12.85, max: $19.18).

What is BIIB's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: BIIB) forecast ROE is 13.49%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.